Invion Limited (ASX: IVX) has signed a funded collaboration with Protect Animal Health Inc. (Taiwan, 7850.TT) to evaluate Photosoft™ in veterinary oncology across in-vitro, in-vivo, and companion-animal studies. Invion supplies compounds, Protect funds, and runs the work. Invion retains all Photosoft IP, with scope to move to a co-development/commercial agreement if results warrant.

Actinogen Medical (ASX: ACW) released two important updates dated 20 October 2025: (1) accelerated recruitment has enabled early closure of pTau screening for the Phase 2b/3 XanaMIA Alzheimer’s trial; and (2) an Advance Overseas Finding (AOF) approval confirms eligibility for a further RDTI rebate of ~$1.87m, taking the total FY25 RDTI to ~$7.36m if the ATO amendment is favourably assessed.

Proteomics International (ASX: PIQ) has expanded its research agreement with the University of Melbourne and the Royal Women’s Hospital (RWH), a leading centre for endometriosis research. The partnership has two clear streams: (1) additional clinical validation for Promarker®Endo—PIQ’s first-in-class blood test for diagnosing endometriosis—and (2) discovery work toward a tissue-specific, next-generation test using peritoneal fluid to improve disease localisation.

Medibank Private has expanded its multi-year funding agreement with Emyria Limited (ASX: EMD) to support screened and eligible customers accessing Empax programs for Treatment-Resistant Depression (TRD) and Post-Traumatic Stress Disorder (PTSD) at Avive Clinic Brisbane (Figure 1). Clinic fit-out and regulatory preparations are underway, with treatment commencement targeted for Q4 CY2025. This marks Emyria’s first insurer-backed program on Australia’s east coast and advances t

Algorae Pharmaceuticals Ltd (ASX: 1AI) has executed a binding term sheet with Cadila Pharmaceuticals Limited for a proposed license and supply agreement covering Australia and New Zealand. The partnership would see Algorae launch two generic medicines targeting cardiovascular and metabolic disorders, with next steps focused on finalising a definitive agreement and preparing for TGA registration.

TrivarX Limited (ASX: TRI) announced a binding option to acquire Stabl-Im™, a stable-isotope MRI platform intended to enable early, repeatable, non-invasive detection and monitoring of brain tumours and metastases—an area with high unmet clinical need and limited safe imaging options. The transaction is paired with a $4.2m placement cornerstoned by Dr Daniel Tillett (founder/CEO of Nucleics and MD/CEO of Race Oncology, ASX: RAC), signalling both technical belief and strategic

Race Oncology Limited (ASX: RAC) has reported a pivotal mechanistic discovery: its lead molecule (E,E)-bisantrene (RCDS1) primarily exerts anticancer activity by binding and stabilising G-quadruplex (G4) structures in DNA and RNA—not via an anthracycline-like pathway. The company positions this as a step-change for clinical strategy, biomarker development, and partnering.

Echo IQ Limited (ASX: EIQ) has delivered a concise update showing rising clinical usage for EchoSolv™ AS, clear progress on EchoSolv™ HF’s FDA pathway, and expanding commercial channels in the US and Europe. The near-term catalysts are anchored in actual hospital integrations, validation work nearing completion, and newly appointed US key opinion leaders guiding adoption.

The Calmer Co. International Limited (ASX: CCO) has reported the strongest quarter in its history with Q1 FY26 sales of $2.4 million, up 26% on Q4 FY25 ($1.9m). Growth was broad-based across Australian retail, the USA, and B2B channels, with additional funding commitments to support inventory and expansion.

Algorae Pharmaceuticals Ltd (ASX: 1AI) has taken a major step toward establishing a commercial presence in the Australian and New Zealand markets. The company has entered into an exclusive licensing agreement with global pharmaceutical manufacturer Sakar Healthcare Limited (NSE: SAKAR, BSE: 538377) (Figure 1) to launch five oncology medicines across the region.

When Race Oncology Limited’s (ASX: RAC) share price doubled at the start of last week, many investors were left asking the same question – what just happened? The answer, as is often the case with biotech catalysts, lies in a combination of significant scientific developments, strong IP positioning, and a clear signal to the market that management is preparing for the next stage of value creation.

On 25 July 2025, Opyl Limited (ASX: OPL) officially rebranded to Pathkey.AI (ASX: PKY) – a move signalling a sharpened focus on applying artificial intelligence to the most critical challenges in clinical trials and drug development. Rather than being “just another med-tech rebrand,” Pathkey.AI represents a company building a sophisticated decision-support ecosystem designed to help therapies get to patients faster, de-risk trials for sponsors, and improve capital efficiency

Founded in Christchurch, New Zealand, in 1984, Ryman Healthcare (NZX: RYM) has grown into one of Australasia’s leading operators of retirement villages and aged care services (Figure 1). For over forty years, the company’s guiding principle has been simple yet powerful — that everything it does must be “good enough for mum and dad.” This philosophy has shaped Ryman’s reputation as a trusted brand, built around its purpose of enhancing freedom, connection, and well-being for o

Race Oncology Limited (ASX: RAC) has announced a major scientific breakthrough that could reshape its commercial and clinical trajectory. The company has discovered that bisantrene – a clinically validated cancer drug – exists as three photoisomers, with only the (E,E)-bisantrene form possessing significant anticancer activity. This discovery has enabled Race to file three new patent applications, potentially providing composition of matter intellectual property (IP) protecti

Proteomics International Laboratories Ltd (ASX: PIQ) has been granted ISO 15189 certification for its Australian laboratory operations – a key milestone that cements its role as a leader in precision diagnostics. This certification validates the company’s systems, processes, and quality management, ensuring accurate and dependable clinical results.